Side-by-side · Research reference

MT-1vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED9/51 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

MT-1

Vesugen

Primary target

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Not applicable — does not operate via hormone axis

Origin

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

MT-1

Vesugen

Standard dose

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

—

Frequency

Every 60 days

Sustained release implant — no daily administration required.

Not specified in available literature

Evidence basis

Phase 3 RCT / FDA-approved orphan drug

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Indication

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

—

Duration

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Case series report treatment courses in elderly arterial insufficiency

Route

Subcutaneous implant — upper arm or abdomen

Subcutaneous or intramuscular

Stability

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

MT-1

Vesugen

Nausea

Common (>10%) — mild, transient

—

Implant site reaction

Erythema, bruising, tenderness at insertion site

—

Hyperpigmentation

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

—

Melanocytic changes

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

—

Headache

Occasional (MC1R-independent melanocortin effects)

—

Photosensitivity (paradoxical)

Rare phototoxic reactions despite melanin increase

—

Contamination risk (unregulated)

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Vesugen

—

Relative Contraindications

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

MT-1

Vesugen

1. Implant insertion

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Site care

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Release kinetics

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Repeat dosing

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Monitoring

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

—

06Stack Synergy

MT-1

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)